Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential. Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027. In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.
North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe. Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end. In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027. Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027. In contrast, Japan will witness a sluggish growth in the market.
By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end. Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules. Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.
Key players identified in FMI’s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.
Request for Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782